Curaleaf has cleared all necessary competition law reviews in Germany and Canada for its Aurora Cannabis acquisition, positioning its October 6, 2026, offer as a more certain path to completion before the December 4, 2026, deadline.
Curaleaf announced it has secured the only two required competition law clearances (Germany on Oct 20/Nov 3, 2026; Canada on Nov 2, 2026) for its enhanced premium bid of Oct 6, 2026 for all Aurora shares. This removes the main regulatory hurdle and raises the probability the offer is completed near the bid terms before the Dec 4, 2026 expiry, which supports Aurora's share price toward the offer value.
The company states all required competition clearances are in hand, which it says strengthens its Oct 6, 2026 offer by adding certainty of completion and a faster path to closing. Lower deal risk on the acquisition is modestly positive for Curaleaf, though the enhanced premium bid and remaining conditions temper the effect.
Curaleaf explicitly contrasts its completed clearances with Organigram's proposed acquisition, which 'remains subject to shareholder, court, and regulatory approvals', and urges Aurora shareholders to weigh this advantage. A weakened competing bid reduces Organigram's chance of winning Aurora and, if it pursues the target, raises the odds of needing to raise its terms.
Curaleaf Holdings has obtained all required competition law clearances in Germany and Canada for its proposed acquisition of Aurora Cannabis. With these regulatory hurdles cleared as of November 3, 2026, Curaleaf aims to bolster its enhanced premium bid of October 6, 2026, ahead of the December 4, 2026 expiry. The company contrasts its progress with the pending status of Organigram's competing proposal.
Both required competition law reviews (Germany and Canada) are complete, so the Curaleaf offer has a clearer and faster path to closing if shareholders tender before the Dec 4, 2026 expiry.
Not certain: the offer still depends on its remaining conditions, and Organigram's competing proposal is still pending its own shareholder, court, and regulatory approvals.
Competition law clearances in Germany and Canada, the only two required jurisdictions, have been received; the offer itself still must satisfy or waive its remaining conditions and expires Dec 4, 2026.
With regulatory risk removed, the acquisition has greater certainty of completion and a faster path to closing, which the company argues strengthens its offer versus Organigram's competing proposal.
Curaleaf argues yes: its own clearances are done while Organigram's proposed acquisition still awaits shareholder, court, and regulatory approvals, giving Curaleaf a certainty and speed advantage.
Organigram's competing proposal is still pending its own approvals, and Aurora's board's response to the offers could still alter the outcome.